HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?
Abstract
Authors
Katharina Wodenitscharow
Katharina Wodenitscharow
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now